Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease.

OBJECTIVE The aim of this study was to assess systematic differences between patients with acute myocardial infarction (MI) and patients with stable angina in matrix metalloproteinase (MMP) circulating levels and genetic polymorphisms. METHODS We identified adults in a large integrated health care delivery system whose initial clinical presentation of coronary disease was either an acute MI or stable exertional angina. A total of 909 patients with acute MI, 466 patients with stable angina, and 1023 healthy older control subjects were genotyped. Serum levels of pro-MMP1, MMP2, MMP3, MMP9, and MMP10 were measured in 199 randomly selected patients from each group. RESULTS At a median of 15 weeks after initial clinical presentation, higher circulating levels of MMP2 and MMP9 were independently associated with acute MI after statistical adjustment for conventional risk factors, hs-CRP levels, and cardiac medications. By contrast, none of the polymorphisms in MMP1, MMP2, MMP3, MMP9, or MMP10 was significantly associated with either acute MI compared with angina, or with coronary disease compared with controls. CONCLUSIONS Circulating levels of MMP2 and MMP9 are independently associated with development of an acute MI rather than stable angina as the initial clinical presentation of coronary artery disease.

[1]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[2]  T. Lehtimäki,et al.  Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene: An Autopsy Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[3]  P. Eriksson,et al.  Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. , 2003, Journal of the American College of Cardiology.

[4]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[5]  A. Henney,et al.  Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1 , 1999, Human Genetics.

[6]  Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. , 1995 .

[7]  O. Takahashi,et al.  Time course of left ventricular remodeling after myocardial infarction: a two-dimensional echocardiographic study. , 2000, Japanese circulation journal.

[8]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[9]  A. Go,et al.  Statin and -Blocker Therapy and the Initial Presentation of Coronary Heart Disease , 2006, Annals of Internal Medicine.

[10]  A. Morgan,et al.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease , 2003, Journal of Molecular Medicine.

[11]  寺島 正浩.  Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction , 2000 .

[12]  A. Zwinderman,et al.  Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. , 1999, The American journal of cardiology.

[13]  P. Talmud,et al.  The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. , 1998, Atherosclerosis.

[14]  Tudor C. Poerner,et al.  Time-Dependent Changes in the Plasma Concentration of Matrix Metalloproteinase 9 after Acute Myocardial Infarction , 2003, Cardiology.

[15]  J. Paramo,et al.  Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. , 2003, Atherosclerosis.

[16]  R. Myers,et al.  Candidate-gene approaches for studying complex genetic traits: practical considerations , 2002, Nature Reviews Genetics.

[17]  D. Tregouet,et al.  Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction , 2005, Circulation research.

[18]  Teruo Inoue,et al.  Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. , 2003, The American journal of cardiology.

[19]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[20]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[21]  V. Znojil,et al.  A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[22]  P. Manow.  ‚The Good, the Bad, and the Ugly‘ , 2002 .

[23]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[24]  D. Brieger,et al.  Elevated circulating levels of matrix metalloproteinase‐9 and ‐2 in patients with symptomatic coronary artery disease , 2005, Internal medicine journal.

[25]  G. Lip,et al.  Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. , 2005, The American journal of cardiology.